Jonah Feldman

In an in-depth interview, Omar Nadeem, MD, explores the promising findings from 20 patients with smoldering myeloma treated with cilta-cel.

The FDA awarded rare pediatric disease and orphan drug designation to the novel small molecule FL118 for osteosarcoma.

A phase 1 trial investigating autologous KMCAR T cells has been initiated in patients with relapsed/refractory multiple myeloma.

Preview ASCO 2026 late-breaking cancer trials—from TNBC ADC survival gains to lung, liver, prostate and myeloma readouts shaping care.

A combination regimen targeting LAG-3 and PD-1 did not significantly extend progression-free survival in advanced melanoma vs single-agent pembrolizumab.

In an interview, Rawan Faramand, MD, discussed her research on cost-effectiveness of graft modification to prevent GVHD in hematopoietic cell transplant.

Gene editing donor cells enabled less toxic targeted maintenance posttransplant; study was not continued for fiscal reasons.

The NEO-CYT trial began treating patients with melanoma in the perioperative setting, combining a novel agent with immune checkpoint inhibitor therapy.

Andrzej Jakubowiak, MD, PhD, explains promising results for KRd maintenance and the potential of modifying the posttransplant maintenance paradigm in multiple myeloma.

First-in-class double-loaded patient-derived immunotherapy joins pancreatic cancer and glioblastoma in FDA Fast Track portfolio; phase 1/2 trial now recruiting.

During a live event, Patrick Hagen, MD, evaluated the safety profile of the MajesTEC-3 regimen and considered the impact of early use of teclistamab in multiple myeloma.

CLOVER-WaM data meet FDA-requested threshold; confirmatory trial planned for fourth quarter 2026.

A first-in-class allogeneic regulatory T-cell therapy advances into multicenter phase 1b/2a trial; trial start expected second half of 2026.

Cilta-cel achieved complete, sustained responses without induction therapy in the precursor disease to multiple myeloma.

Rashmi Chugh, MD, discusses the outcomes and goals of a promising study for ozekibart plus chemotherapy in patients with relapsed Ewing sarcoma.

Jakafi XR offers bioequivalent alternative to twice-daily formulation; pharmacy availability expected by May 8.

The second-generation T-cell immunotherapy Orca-Q demonstrated encouraging outcomes in an ongoing phase 1 trial.

The oral gamma secretase inhibitor varegacestat improved progression-free survival and overall response rate vs placebo; full results to be presented at ASCO.

The BCMA-CD3 bispecific antibody outperformed daratumumab plus pomalidomide and dexamethasone in double-class exposed patients.

The DNA ImmunoBody therapy improved efficacy when added to ipilimumab and nivolumab, with a registrational phase 3 trial expected to begin later this year.

Longer follow-up from the NMDP's ACCESS trial emphasizes the opportunity to use mismatched stem cell donors in more diverse patient populations.

With long-term follow-up, HLA-A*02:01–positive patients with metastatic uveal melanoma maintained survival benefit with the bispecific agent vs investigator's choice.

As regulators examine the on-body injector used with isatuximab in multiple myeloma, Sikander Ailawadhi, MD, provides commentary on frequently asked questions.

The target date for the FDA's decision on isatuximab via on-body injector is now July 23, 2026.

mRNA-4359 demonstrated high response rates and antigen-specific T-cell activation in a small cohort of previously untreated patients.

Gut microbiome bacteria are linked to risk of recurrence after treatment with immunotherapy for resectable melanoma.

A brain-penetrant pan-RAF/MEK molecular glue demonstrated a 38% response rate in a heavily pretreated melanoma population that currently has no approved targeted therapies.

ODD status was granted based on tumor response rates with eftilagimod alfa and pembrolizumab of more than 3-fold above historical benchmarks from radiotherapy alone.

The FDA granted FTD to OPN-6602, an oral EP300/CBP inhibitor currently used in a first-in-human phase 1 trial.

Oral darovasertib plus crizotinib doubled PFS and boosts responses in first-line HLA-A*02:01–negative metastatic uveal melanoma; FDA submission process is underway.